FDA

FDA
The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel).
FDA
FEATURED STORIES
FDA
A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, if his CBER counterpart Vinay Prasad tries to supersede Pazdur’s authority, “there will be hell to pay.”
Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and feasibility of the Commissioner’s National Priority Voucher program.
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
FDA
Tauvid is the first and only approved diagnostic agent for imaging tau neurofibrillary tangles (NFTs) in the brain.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
FDA
Bristol Myers Squibb is doing its best to claim market share in the checkpoint inhibitor space and over the past month, the company is pushing its way forward with a pair of regulatory approvals in lung cancer.
FDA
To date, Dupixent is the only biologic approved for this age group.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
FDA
“Today’s approval of Kynmobi advances treatment options for people with Parkinson’s disease who experience OFF episodes and the associated disruption of everyday activities,” said Antony Loebel, Sunovion’s president and chief executive officer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.